Literature DB >> 16357320

Selective activation of TACI by syndecan-2.

Daniela Bischof1, Sherine F Elsawa, George Mantchev, Juhan Yoon, Grace E Michels, Allan Nilson, Shari L Sutor, Jeffrey L Platt, Stephen M Ansell, Gotz von Bulow, Richard J Bram.   

Abstract

B-lymphocyte homeostasis and function are regulated by complementary actions of the TNFR family members TACI, BCMA, and BAFF-R, which are expressed by mature B cells. How these receptors are differentially activated is not entirely understood, because the primary ligand BAFF binds to all three. We searched for alternative ligands for TACI using recombinant TACI-Fc fusion protein as a probe and identified syndecan-2 as a new binding partner. TACI binding appears to require heparan sulfate posttranslational modifications of syndecan-2, because free heparin or pretreatment with heparitinase blocked the interaction. Syndecan-2 bound TACI but bound neither BAFF-R nor BCMA. Transfected cells expressing syndecan-2 activated signaling through TACI, as indicated by an NFAT-specific reporter. Syndecan-1 and syndecan-4 were also able to induce TACI signaling in a similar manner. This is the first identification of ligands that selectively activate TACI without simultaneously triggering BCMA or BAFF-R. This finding may help explain the alternative outcomes of signaling from this family of receptors in B cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16357320      PMCID: PMC1895754          DOI: 10.1182/blood-2005-01-0256

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  61 in total

1.  Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway.

Authors:  Catherine Kern; Jean-Francois Cornuel; Christian Billard; Ruoping Tang; Danielle Rouillard; Virginie Stenou; Thierry Defrance; Florence Ajchenbaum-Cymbalista; Pierre-Yves Simonin; Sophie Feldblum; Jean-Pierre Kolb
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

2.  Impaired IgA class switching in APRIL-deficient mice.

Authors:  Emanuela Castigli; Sumi Scott; Fatma Dedeoglu; Paul Bryce; Haifa Jabara; Atul K Bhan; Emiko Mizoguchi; Raif S Geha
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-26       Impact factor: 11.205

3.  Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system.

Authors:  A Aruffo; B Seed
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

4.  Selective extraction of polyoma DNA from infected mouse cell cultures.

Authors:  B Hirt
Journal:  J Mol Biol       Date:  1967-06-14       Impact factor: 5.469

5.  Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome.

Authors:  Anne J Novak; Deanna M Grote; Mary Stenson; Steven C Ziesmer; Thomas E Witzig; Thomas M Habermann; Brandon Harder; Kay M Ristow; Richard J Bram; Diane F Jelinek; Jane A Gross; Stephen M Ansell
Journal:  Blood       Date:  2004-07-13       Impact factor: 22.113

6.  BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.

Authors:  Jérôme Moreaux; Eric Legouffe; Eric Jourdan; Philippe Quittet; Thierry Rème; Cécile Lugagne; Philippe Moine; Jean-François Rossi; Bernard Klein; Karin Tarte
Journal:  Blood       Date:  2003-12-04       Impact factor: 22.113

7.  TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology.

Authors:  Yoshiteru Sasaki; Stefano Casola; Jeffery L Kutok; Klaus Rajewsky; Marc Schmidt-Supprian
Journal:  J Immunol       Date:  2004-08-15       Impact factor: 5.422

Review 8.  Syndecans-2 and -4; close cousins, but not identical twins.

Authors:  Eok-Soo Oh; John R Couchman
Journal:  Mol Cells       Date:  2004-04-30       Impact factor: 5.034

9.  Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations.

Authors:  F Mackay; S A Woodcock; P Lawton; C Ambrose; M Baetscher; P Schneider; J Tschopp; J L Browning
Journal:  J Exp Med       Date:  1999-12-06       Impact factor: 14.307

10.  BCMA is essential for the survival of long-lived bone marrow plasma cells.

Authors:  Brian P O'Connor; Vanitha S Raman; Loren D Erickson; W James Cook; Lehn K Weaver; Cory Ahonen; Ling-Li Lin; George T Mantchev; Richard J Bram; Randolph J Noelle
Journal:  J Exp Med       Date:  2004-01-05       Impact factor: 14.307

View more
  23 in total

1.  Heparan sulfate proteoglycans, Fc receptors, and DC suppression.

Authors:  Eddy Roosnek; Pascal Schneider; Bertrand Huard
Journal:  Blood       Date:  2008-08-01       Impact factor: 22.113

2.  Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma.

Authors:  Andrea Schmidts; Maria Ormhøj; Bryan D Choi; Allison O Taylor; Amanda A Bouffard; Irene Scarfò; Rebecca C Larson; Matthew J Frigault; Kathleen Gallagher; Ana P Castano; Lauren S Riley; Maria L Cabral; Angela C Boroughs; Rubí M-H Velasco Cárdenas; Wolfgang Schamel; Jing Zhou; Sean Mackay; Yu-Tzu Tai; Kenneth C Anderson; Marcela V Maus
Journal:  Blood Adv       Date:  2019-11-12

Review 3.  The Tumor Necrosis Factor Family: Family Conventions and Private Idiosyncrasies.

Authors:  David Wallach
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-10-01       Impact factor: 10.005

4.  Gene cloning, expression and functional characterization of a proliferation-inducing ligand (APRIL) from hedgehog (Erinaceus europaeus).

Authors:  Xian-Wei Cui; Wen Xiao; Chen-Bo Ji; Ai-Ying Tian; Jie Zhang; Shuang-Quan Zhang
Journal:  Mol Biol Rep       Date:  2012-01-14       Impact factor: 2.316

5.  Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency: clinical and immunologic outcomes in heterozygotes.

Authors:  Li Zhang; Lin Radigan; Ulrich Salzer; Timothy W Behrens; Bodo Grimbacher; George Diaz; James Bussel; Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol       Date:  2007-11       Impact factor: 10.793

6.  Dominant-negative effect of the heterozygous C104R TACI mutation in common variable immunodeficiency (CVID).

Authors:  Lilit Garibyan; Adrian A Lobito; Richard M Siegel; Matthew E Call; Kai W Wucherpfennig; Raif S Geha
Journal:  J Clin Invest       Date:  2007-05-10       Impact factor: 14.808

7.  The design and characterization of receptor-selective APRIL variants.

Authors:  Fiona C Kimberley; Almer M van der Sloot; Marco Guadagnoli; Katherine Cameron; Pascal Schneider; J Arnoud Marquart; Miranda Versloot; Luis Serrano; Jan Paul Medema
Journal:  J Biol Chem       Date:  2012-09-07       Impact factor: 5.157

8.  TACI, isotype switching, CVID and IgAD.

Authors:  Emanuela Castigli; Raif S Geha
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

9.  A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation.

Authors:  Mamta Gupta; Stacey R Dillon; Steven C Ziesmer; Andrew L Feldman; Thomas E Witzig; Stephen M Ansell; James R Cerhan; Anne J Novak
Journal:  Blood       Date:  2009-03-25       Impact factor: 22.113

10.  Synovial tissues concentrate secreted APRIL.

Authors:  Cem Gabay; Veit Krenn; Carine Bosshard; Christian Alexander Seemayer; Carlo Chizzolini; Bertrand Huard
Journal:  Arthritis Res Ther       Date:  2009-09-29       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.